Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Moderna : Positive pre-clinical data for CureVac's COVID-19 vaccine

10/23/2020 | 08:05am EST

BERLIN, Oct 23 (Reuters) - German biotech company CureVac said on Friday its potential vaccine against the coronavirus triggered an immune response in pre-clinical animal studies.

The Tuebingen-based company, which is backed by the Bill & Melinda Gates Foundation, said the potential vaccine, known as CVnCoV, produced neutralising antibodies and activated T-cells in hamsters and mice.

CureVac is using the so-called messenger RNA approach, the same as rivals BioNTech and its partner Pfizer as well as Moderna, which have started testing on humans.

CureVac said the vaccine also reduced the levels of replicating virus in the upper respiratory tract and protected the lungs of hamsters when they were exposed to a live virus.

"The pre-clinical data published today show that our COVID-19 vaccine candidate has the potential to induce an efficacious and balanced immune response, mimicking the natural immune defence and providing lung protection in a relevant challenge model,” said CureVac Chief Technology Officer Mariola Fotin-Mleczek.

Shares in CureVac were up 7.8% at 1148 GMT.

The potential vaccine is currently being tested in humans in early and mid-stage trials, and CureVac said it expected to publish interim Phase I data shortly. (Reporting by Caroline Copley; editing by Jason Neely and Mark Potter)


© Reuters 2020
All news about MODERNA, INC.
10:15aCVS, Walgreens Gear Up to Deliver Covid-19 Vaccines to Nursing Homes
DJ
08:01aMODERNA : applies for regulatory authorisation for COVID-19 vaccine
AQ
07:59aMODERNA : Drugmaker Merck divests stake in vaccine-maker Moderna
RE
07:54aMODERNA : Drugmaker Merck divests stake in vaccine-maker Moderna
RE
07:40aPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 3rd Update
DJ
05:50aPFIZER-BIONTECH'S COVID-19 VACCINE A : What You Need to Know
DJ
04:10aPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 2nd Update
DJ
03:06aPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- Update
DJ
02:05aJGBs steady to lower on stimulus, vaccine hopes
RE
01:56aS.Korea shares post record closing high on chip sector outlook
RE
More news
Financials (USD)
Sales 2020 449 M - -
Net income 2020 -673 M - -
Net cash 2020 2 584 M - -
P/E ratio 2020 -95,6x
Yield 2020 -
Capitalization 55 799 M 55 799 M -
EV / Sales 2020 119x
EV / Sales 2021 7,40x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 114,35 $
Last Close Price 141,01 $
Spread / Highest target 31,2%
Spread / Average Target -18,9%
Spread / Lowest Target -57,4%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.655.04%55 799
LONZA GROUP AG56.57%45 596
CELLTRION, INC.90.06%41 539
IQVIA HOLDINGS INC.10.82%32 829
SEAGEN INC.55.27%31 988
IMMUNOMEDICS, INC.315.22%20 324